Cancer cell plasticity and therapeutic resistance: mechanisms, crosstalk, and translational perspectives

Area of Science:

• Oncology
• Cancer Biology
• Molecular Medicine

Background:

• Drug resistance in targeted cancer therapies poses a significant challenge to patient outcomes.
• Malignant cells exhibit biological flexibility, enabling tolerance and resistance to treatments.
• Slow-cycling drug-resistant cells can develop permanent resistance or regain sensitivity after therapy cessation.

Purpose of the Study:

• To explore the concept of cancer cell adaptability in the context of targeted therapies.
• To deepen the understanding of tumor cell plasticity and its role in drug resistance and heterogeneity.
• To identify cellular, molecular, and genetic processes governing cancer cell adaptability for improved therapeutic strategies.

Main Methods:

• Analysis of cellular signaling pathways involved in cancer cell adaptability.
• Investigation of tumor microenvironment interactions influencing drug resistance.
• Examination of genetic and epigenetic alterations contributing to cancer cell plasticity.

Main Results:

• Cancer cell adaptability, characterized by drug resistance and heterogeneity, is linked to alterations in signaling, microenvironment, and genetic/epigenetic factors.
• Understanding these adaptive mechanisms is crucial for predicting treatment response and developing novel therapeutic approaches.
• Targeting specific biological pathways and employing combination therapies are identified as effective strategies.

Conclusions:

• Comprehending cancer cell adaptability is essential for advancing cancer therapy methodologies.
• Identifying the drivers of tumor heterogeneity and drug resistance will facilitate personalized and effective cancer treatments.
• Further research into cancer cell plasticity promises improved patient outcomes through tailored therapeutic interventions.